Erratum: The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis (PLoS ONE (2014) 9:12 (e115103) DOI: 10.1371/journal.pone.0115103);The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Mao, Yan ^a   Qu, Qing ^a   Zhang, Yuzi ^a   Liu, Junjun ^a   Chen, Xiaosong ^a   Shen, Kunwei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; LAPATINIB; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR FOXP3; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER TISSUE; CD8+ T LYMPHOCYTE; HISTOPATHOLOGY; HUMAN; LYMPHOCYTIC INFILTRATION; META ANALYSIS; PREDICTIVE VALUE; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; TUMOR VOLUME; ADJUVANT THERAPY; ADVERSE EFFECTS; BREAST NEOPLASMS; FEMALE; IMMUNOLOGY; ODDS RATIO; STATISTICAL MODEL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MODELS, STATISTICAL; NEOADJUVANT THERAPY; ODDS RATIO; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84918537575     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119243     Document Type: Erratum

References (55)

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1): 9-29.
2. Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, et al. (2013) Molecular pathways:involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res 19(1): 28-33.
3. Caras I, Grigorescu A, Stavaru C, Radu D, Mogos I, et al. (2004) Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother 53(12): 1146-1152.
4. Tomsova M, Melichar B, Sedlakova I, Steiner I (2008) Prognostic significance of CD3+ tumorinfiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 108(2): 415-420.
5. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, et al. (2003) Intratumoral Tcells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3): 203-213.
6. De Jong RA, Leffers N, Boezen HM, van der Zee AGJ, Hollema H, et al. (2009) Presence of tumorinfiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol 114(1): 105-110.
7. Giatromanolaki A, Bates GJ, Koukourakis MI, Sivridis E, Gatter KC, et al. (2008) The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol Oncol 110(2): 216-221.
8. Ino K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, et al. (2008) Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 14(8): 2310-2317.
9. Kondratiev S, Sabo E, Yakirevich E, Lavie O, Resnick MB (2004) Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res 10(13): 4450-4456.
10. Yamagami W, Susumu N, Tanaka H, Hirasawa A, Banno K, et al. (2011) Immunofluorescencedetected infiltration of CD4+ FOXP3+ regulatory T cells is relevant to the prognosis of patients with endometrial cancer.Int J Gynecol Cancer 21(9): 1628-1634.
11. Loi S, Sirtaine N, Piette F, Sagado R, Viale G, et al. (2013) Prognostic and predictive value of tumorinfiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31(7): 860-867.
12. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, et al. (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29(15): 1949-1955.
13. Menard S, Tomasic G, Casalini P, Balsari A, Pilotti S, et al. (1997) Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 3(5): 817-819.
14. Mohammed ZM, Going JJ, Edwards J, Elsberger B, Doughty JC, et al. (2012) The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer 107(5): 864-873.
15. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, et al. (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21(22): 4165-4174.
16. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, et al. (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15(7): 2483-2493.
17. Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, et al. (2012) Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage IIII breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet oncol 13(9): 869-878.
18. Fisher CS, Ma CX, Gillanders WE, Aft RL, Eberlein TJ, et al. (2012) Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response. Ann Surg Oncol 19(1): 253-258.
19. Kong X, Moran MS, Zhang N, Haffty B, Yang Q (2011) Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer 47(14): 2084-2090.
20. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, et al. (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8): 1275-1281.
21. Denkert C, Loibl S, Muller BM, Eidtmann H, Schmitt WD, et al. (2013) Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann oncol 24(11): 2786-2793.
22. Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, et al. (2011) Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC cancer 11: 486.
23. Ohno S, Chow LW, Sato N, Masuda N, Sasano H, et al. (2013) Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil- epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res Treat 142(1): 69-80.
24. Aruga T, Suzuki E, Saji S, Horiguchi S, Horiguchi K, et al. (2009) A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. Oncol Rep 22(2): 273-278.
25. Denkert C, Loibl S, Noske A, Roller M, Mü ller BM, et al. (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(1): 105-113.
26. Issa-Nummer Y, Darb-Esfahani S, Loibl S, Kunz G, Nekljudova V, et al. (2013) Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer-a substudy of the neoadjuvant GeparQuinto trial. PloS One 8(12): e79775.
27. Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, et al. (2008) Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumorinfiltrating foxp3+ regulatory T cells. Clin Cancer Res 14(8): 2413-2420.
28. Liu F, Li Y, Ren M, Zhang X, Guo X, et al. (2012) Peritumoral FOXP3(+) regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3(+) regulatory T cell is prognostic predictor of breast cancer patients. Breast Cancer Res Treat 135(2): 459-467.
29. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, et al. (2013) Prognostic and predictive value of tumorinfiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31(7): 860-867.
30. Oda N, Shimazu K, Naoi Y, Morimoto K, Shimomura A, et al. (2012) Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients. Breast Cancer Res Treat136(1): 107-116.
31. Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, et al. (2012) Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat 132(3): 793-805.
32. Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, et al. (2013) Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 09(10): 2705-2713.
33. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, et al. (2011) Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res13(6): R126.
34. Yamaguchi R, Tanaka M, Yano A, Tse GM, Yamaguchi M, et al. (2012) Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Human Pathol 43(10): 1688-1694.
35. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, et al. (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25(8):1544-1550.
36. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, et al. (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29(15): 1949-1955.
37. Mcshane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93(4): 387-391.
38. Hayes DF, Ethier S, Lippman ME (2006) New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer ResTreat 100(2): 237-238.
39. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple graphical test. BMJ 315: 629-634.
40. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1010.
41. Denkert C, Loibl S, Salat C, Sinn BV, Schem C, et al. (2013) Increased tumor-associated lymphocytes predict benefit froom additioin of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG66/AGO-B). Cancer Res 73(24 Suppl): Abstract nr S1-06.
42. Lee HJ, Seo JY, Ahn JH, Ahn SH, Gong G (2013) Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer 16(1): 32-39.
43. Loi S, Jose VL, Bono P, Sirtaine N, Jose V, et al. (2013) Tumor infiltrating lymphocytes (TIL) indecate trastuzumab benefit in early-stage HER2-positive breast cancer. Cancer Res 73(24 Suppl): Abstract nr S1-05.
44. Mei Z, Liu Y, Liu C, Cui A, Liang Z, et al. (2014) Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer 110(6): 1595-1605.
45. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, et al. (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16(8): 2672-2685.
46. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97(3): 188-194.
47. Van Der Hage JA, Van De Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, et al. (2001) Preoperative chemotherapy in operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19(22): 4224-4237.
48. Hornychova H, Melichar B, Tomsova M, Mergancova J, Urminska H, et al. (2008) Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Inves 26(10): 1024-1031.
49. Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, et al. (2010) Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer 116(6): 1431-1439.
50. Straver ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, et al. (2010) The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Sur Oncol 17(9): 2411-2418.
51. Tan MC, Al Mushawah F, Gao F, Aft RL, Gillanders WE, et al. (2009) Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am J Surg 198(4): 520-525.
52. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, et al. (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8): 2329-2334.
53. Melichar B, Hornychova H, Kalabova H, Bašová H, Mergancová J, et al. (2012) Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma: a retrospective analysis. Med oncol 29(4): 2577-2585.
54. Montagna E, Bagnardi V, Rotmensz N, Viale G, Pruneri G, et al. (2010) Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Res Treat 124(3): 689-699.
55. García-Martínez E, Luengo-Gil G, Chaves A, Gonzalez-Billalabeitia E, García GT, et al. (2013) Changes induced by neoadjuvant chemotherapy (NCT) in breast cancer infiltrating lymphocytes (TIL) subpopulations are associated with chemo-sensitivity and prognosis. Cancer Res 73(24 Suppl): P5-01-08.